PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent an eleman Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork-Reduction Act of 1995, no person re required to respond to a collection of information unless it di a valid OMB control number Complete if Known Substitute for form 1449A/PTO Applicati n Number 09/783,320 **SUPPLEMENTAL** Filing Dat 02/15/01 **First Named Inventor** Walke INFORMATION DISCLOSURE 1043 Group Art Unit STATEMENT BY APPLICANT RAMIREZ To be assigned Examiner Name of Sheet Attorney Docket Number LEX-0137-USA

				U.S. PATENT DOCUMEN	TS	
Examiner nitials*	Cite No. ¹	U.S. Patent Document Kind Code ² Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
M	BZ	5,817,479	B1	Au-Young et al.	10/06/98	
1717	CA	6,013,455	B1	Bandman et al.	01/11/00	
	, ·	MIENT				
	zd.is.	1700				
		in the second				
	, S	931 3				

				FORE	IGN PATENT DOCUMENTS	3		
Examiner Initials*	Cite No.¹	Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
		Office	³ Number ⁴	Kind Code⁵ (<i>if known</i>)	Applicant of Cited Document	cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T⁵
Me	СВ	wo	99/20747	A2	Janssen Pharmaceutica NV	04/29/99		
M	СС	EP	1074617	A2	Helix Research Institute	02/07/01		
,								
-								

Examiner Signature	Al	Date Considered	5/8/	2002
Signature	TIT	 Considered	<u> </u>	000

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

#7

^{*}EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/99. OMB 0651-0031 d Trademark Office; U.S. DEPARTMENT OF COMMERCE

Inder the P	aperwork Reduction Act of 1995,	no persons are required to	respond to a collection of information u	inless it displays a valid OMB control number.		
Subs	stitute for form 1449B/PTO		Complete if Known			
	SUPPLEMEN	ITAI	Applicati n Number	09/783,320		
			Filing Date	02/15/01		
INFC	PRMATION DISC	CLOSURE	First Named Inv ntor	Walke		
STA	TEMENT BY AF	PLICANT	Group Art Unit	1843- 1652		
			Examiner Name	To be assigned RAMIREZ		
Sheet	of	2	Attorney Docket Number	LEX-0137-USA		

	,;		
		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include rame of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
TOR	CD	Datebas 2 MBL Sequence Database (Online) Hinxton, UK; May 27, 1999, KOEHRER et al., "Homo sapiens mRNA, cDN DKFZp364L2416 (from clone DKFZp56L2416)," XP002176933, EMBL:HSM800531; Accession no. AL050385; abstract	A
M	CE	Database EMBL Sequence Database (Online) Hinxton, UK; July 6, 1999, SCANLAN et al., "Homo sapiens NY-REN-55 Antigen mRNA, partial cds.," XP002176934, EMBL Accession no. AF155113; abstract	
D12	CF	Database EMBL Database (Online), Hinxton, UK; Febraury 16, 1993, LETWIN et al., "nek1=serine/threonine-and tyrosine specific protein kinase (mice, erythroleukemia cells, mRNA 4263 nt)", XP002176935, EMBL Accession no. S45828; abstract	
8R	CG	LETWIN et al., "A mammalian dual specificty protein kinase, Nek1, is related to the NIMA cell cycle regulator and highly expressed in meiotic germ cells," Embo J., Vol. 11, No. 10, October 1992, pgs. 3521-3531, XP002176931	
OR	СН	Database GENSEQ (Online) Washington, US; April 17, 2000, HILLMAN et al., "Human protein kinase homologue," XP002176938, NAGENSEQ:AAZ86797; AAGENSEQ:AAY76753; abstract	
DR	CI	Database GENSEQ (Online) Washington, US; June 26, 2001, OTA et al., "Human protein sequence SEQ ID No. 17342," XP002176937, AAGENSEQ:AAH17731, Accession no. AAH17731; AAGENSEQ:AAB95221, Accession no. AAB95221; abstract	
m	Cì	BEATCH et al., "The tight junction protein ZO-2 contains three PDZ (PSD-95/discs-large/ZO-1) domains and an alternatively spliced region," Journal of Biological Chemistry, Vol. 271, No. 42, 1996, pgs. 25723-25726, XP002176932; ISSN: 0021-9258	
M	СК	SCANLAN et al, "Antigens Recognized by Autologous Antibody in Patents with Renal-Cell Carcinoma," Int. J. Cancer, Vol. 83, 1999, pp. 456-464	
DR	CL	International Search Report, International Application No. PCT/US01/05356, 09/25/01 (Attorney Docket No. LEX-0137-PCT)	
		<u> </u>	_
L	L		1

	^		
Examiner	AX Y	Date	-/~/22
Signature -		Considered	5.18.1800 L

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.